|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to many factors including lack of awareness and lack of prostate-specific antigen (PSA) screening, a high percentage of men present with locally advanced and metastatic prostate cancer at diagnosis.
|
31297628 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The median PSA at date of diagnosis decreased with 46% from 181 ng/mL in 1998 to 98 ng/mL in 2015.<b>Conclusions:</b> There was an increase in survival among men with <i>de novo</i> metastatic prostate cancer in Sweden between 1998 and 2015.
|
31526166 |
2020 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HORRAD trial is a multicentre RCT recruiting 432 patients with prostate-specific antigen (PSA) >20ng/ml and primary bone mPCa on bone scan between 2004 and 2014.
|
30266309 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate Cox regression analysis demonstrated that Gleason grade group, prostate-specific antigen nadir (nPSA), and time to PSA nadir (TTN) were risk factors for progression to CRPC in mPCa patients.
|
31632505 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fifty-two patients with metastatic PCa who underwent [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT imaging and serum prostate-specific antigen (PSA) level measurements before and during treatment were investigated.
|
31468235 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Overall, our results confirmed the HALP score as an independent prognostic factor for PSA-PFS in patients with mPCA or oPCA after cRP.
|
30662528 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 121 consecutive patients with recurrent PC as defined by PSMA-ligand PET (median PSA: 1.13ng/ml) underwent PSMA-targeted RGS.
|
30987843 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eligibility included metastatic prostate cancer and at least one: small-cell neuroendocrine morphology; ≥50% neuroendocrine marker expression; new liver metastases without PSA progression; or elevated serum neuroendocrine markers.
|
30232224 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (<100 ng ml<sup>-1</sup>), intermediate (100-999 ng ml<sup>-1</sup>), and high (≥1000 ng ml<sup>-1</sup>).
|
29735818 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.
|
29194902 |
2019 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
|
29663462 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the metastatic prostate cancer cohort, the expression of four microRNAs (miRNA-125b, -126, -143 and -221), and miRNA-141 in tissue was associated with Gleason score and prostate-specific antigen, respectively.
|
29775158 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of the current study was to evaluate the factors and outcomes associated with increased imaging and serum prostate-specific antigen use in men with mPCa.
|
29579318 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
|
29855278 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our clinical observations demonstrate that CTL immunotherapy is a viable treatment option for PC patients, particularly those with bone metastatic lesions and high serum levels of PSA and FPSA.
|
29901632 |
2018 |
|
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A retrospective analysis of a single-institution cohort of men with castration-resistant, metastatic prostate cancer was performed to determine the association between carrier status of pathogenic BRCA2 germline variants and prostate-specific antigen response to carboplatin-based chemotherapy.
|
28608931 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively evaluated the utility of <sup>68</sup>Ga-PSMA-11 PET for planning <sup>223</sup>RaCl<sub>2</sub> therapy of patients with metastatic prostate cancer and its impact on the therapeutic response as determined by prostate-specific antigen (PSA) and alkaline phosphatase (ALP), as well as the correlation of PSA changes with the results of prostate-specific membrane antigen (PSMA) PET follow-up scans.
|
27660148 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with PSA value > 4 ng/ml and clinical suspicion of PCa were included.
|
29050295 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the interim, we propose a practical approach to prostate cancer screening for men with a germline mutation in a known/suspected moderate to high-penetrance cancer predisposition gene (eg, BRCA1/2), and/or men with a first- or second-degree relative with metastatic prostate cancer (regardless of genetic testing): baseline prostate-specific antigen and digital rectal exam by experienced providers at age 40 years or 5 years earlier than age of diagnosis of the youngest first- or second-degree relative with metastatic prostate cancer, whichever is earlier.
|
28697982 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic prostate cancer in the modern era of PSA screening.
|
28338310 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eligible patients had metastatic prostate cancer and a PSA level higher than 4.0 ng/mL between 6 and 12 months after starting ADT.
|
28358937 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the context of chemotherapy in metastatic prostate cancer, we show that a variety of patterns for the Prostate Specific Antigen (PSA) kinetics can be captured by using a mechanistic model defined by nonlinear ordinary differential equations.
|
27148956 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate specific antigen based screening among men receiving 5α-reductase inhibitors did not improve the detection of high grade or metastatic prostate cancer, or prevent prostate cancer death.
|
28216328 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy.
|
26585698 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed outcomes in men with low prostate specific antigen and a high disease burden who received the oral androgen receptor inhibitor enzalutamide in the PREVAIL (Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer) study.
|
28736322 |
2017 |